MT-1
Melanotan-1 (Afamelanotide)
FDA-approved melanocortin for sun-sensitivity conditions
Melanotan-1 (afamelanotide) is a synthetic analog of alpha-MSH that stimulates melanin production. It is the only melanocortin peptide with regulatory approval, licensed for erythropoietic protoporphyria (EPP).
Admin routes
Subcutaneous (implant)
Popularity
Niche
Side effects
Generally mild
AU vendors
0 rated
✓Key benefits
📈What to expect
Initial skin darkening begins after implant insertion
Full tanning effect and UV protection established
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
EPP (approved use)
16 mg implant
Subcutaneous implant every 60 days
Ongoing as needed for sun protection
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|FDA and EMA approved for erythropoietic protoporphyria
Overview
Afamelanotide (brand name Scenesse) is a linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) developed at the University of Arizona. Unlike melanotan-2, which is cyclic and activates multiple melanocortin receptors, MT-1 is more selective for MC1R, the receptor primarily responsible for melanin production. It was approved by the EMA in 2014 and the FDA in 2019 for erythropoietic protoporphyria (EPP), a painful genetic condition where sunlight causes burning pain in the skin. By increasing melanin production, afamelanotide provides photo-protection for EPP patients. It is administered as a subcutaneous implant every 60 days.
⚙️How it works
Afamelanotide is a selective MC1R agonist. MC1R activation in melanocytes triggers the cAMP/PKA/CREB pathway, which upregulates tyrosinase and other melanin synthesis enzymes. This increases eumelanin production (the protective brown-black pigment), resulting in skin darkening and increased UV protection. Unlike MT-2, it has minimal activity at MC3R and MC4R, so it produces less appetite suppression and sexual side effects.
⚡Side effects
📅Research history
MT-1 developed at the University of Arizona by Hruby and Hadley
EMA approves afamelanotide (Scenesse) for EPP
FDA approves Scenesse for EPP in the United States
MT-1 vs MT-2
Both are alpha-MSH analogs that increase melanin production, but they are different compounds. MT-1 (afamelanotide) is linear, more selective for MC1R, has regulatory approval, and is used as a 60-day implant. MT-2 (melanotan-2) is cyclic, less selective (activates MC3R and MC4R too), has no regulatory approval, and is used as daily subcutaneous injections. MT-2 causes more side effects (nausea, libido changes, appetite effects) but is the version most commonly used in the tanning community due to its availability and stronger tanning effect.
References
- [1]Clinuvel Pharmaceuticals. 'SCENESSE (afamelanotide) prescribing information.' 2019.
- [2]Langendonk JG, et al. 'Afamelanotide for erythropoietic protoporphyria.' New England Journal of Medicine, 2015.
Frequently asked questions
Related peptides
Community experiences
Share your experience with MT-1. Effects, side effects, protocol details - help others make informed decisions.
No community reviews yet. Be the first to share your experience with MT-1.
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for MT-1.
Open CalculatorFound this useful?
Share this guide
Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.